recent articles
Exclusive: combination of drugs causes tumours to vanish in some terminally ill patients, study finds A new cancer treatment can wipe out tumours in terminally ill head and neck cancer patients, scientists have discovered. In a landmark...
Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...
More interesting news around PD-L1 for use in Classical Hodgkin lymphoma with specific indications as below. Another increasingly common example of companion diagnostics and personalized immunotherapies. On May 17, 2016, the U.S. Food and Drug...
© 2023 Tissuepathology.com. All rights reserved. Millennial Consulting. | Web Design by Zealth Digital Marketing